Trial Profile
The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigen
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2018
Price :
$35
*
At a glance
- Drugs CHP-MAGE-A4 (Primary) ; Picibanil
- Indications Cancer
- Focus Adverse reactions; Pharmacodynamics
- 07 Mar 2018 New trial record
- 01 Mar 2018 Results (n=16) assessing predictive role of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in peripheral blood mononuclear cells (PBMCs) in patients receiving 300 microgram of CHP-MAGE-A4 and 0.5 Klinische Einheit (KE) of OK432 published in the Anticancer Research